Loading
Loading
Research Overview
Potent NNMT (nicotinamide N-methyltransferase) inhibitor; NNMT normally consumes methyl donors that would otherwise support NAD+ synthesis, so its inhibition raises intracellular NAD+ and SAM levels, increasing mitochondrial activity and reducing lipid accumulation in preclinical models.
Overview
5-Amino-1MQ is a cell-permeable NNMT inhibitor studied in preclinical settings for its ability to reduce NNMT enzymatic activity and alter NAD+ metabolism. By inhibiting NNMT, the compound reduces nicotinamide catabolism, potentially elevating intracellular NAD+ pools and influencing sirtuin activity, epigenetic methyl donor availability, and adipocyte biology.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, 5-amino-1mq (nnmt inhibitor) has no TGA approval for therapeutic use. It is sold by Capital Precision Labs strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Potent NNMT (nicotinamide N-methyltransferase) inhibitor; NNMT normally consumes methyl donors that would otherwise support NAD+ synthesis, so its inhibition raises intracellular NAD+ and SAM levels, increasing mitochondrial activity and reducing lipid accumulation in preclinical models.
Support
Available from Capital Precision Labs
For research use only. Capital Precision Labs products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
